Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1176753 | 0.91 | L3MBTL1 (0.43) | MRGPRX4L3MBTL1GLATDP1HSP90B1 | |
| Methyl Benzoate SCHEMBL8468464 | 0.90 | TSHR (0.43) | MRGPRX4L3MBTL1GLATDP1HSP90B1 | |
| SCHEMBL171010 | 0.88 | MAOA (0.48) | KDM4EL3MBTL1GLATDP1HSP90B1 | |
| SCHEMBL8006592 | 0.83 | KMT2A (0.38) | KDM4EL3MBTL1GLAHSP90B1TRAP1 | |
| SCHEMBL4745471 | 0.82 | CXCR5 (0.42) | KDM4EL3MBTL1GLALMNAMAPT | |
| SCHEMBL8006594 | 0.82 | MAOA (0.37) | L3MBTL1GLAHSP90B1TRAP1LMNA | |
| Ether SCHEMBL1723031 | 0.81 | MAOA (0.41) | LMNAMAPTMEN1KMT2APOLB | |
| SCHEMBL28207675 | 0.77 | MAOA (0.42) | KDM4ELMNAMAPTMEN1KMT2A | |
| Xanthene SCHEMBL27773733 | 0.77 | MAOA (0.65) | KDM4EL3MBTL1TDP1MEN1KMT2A | |
| Ether SCHEMBL1176750 | 0.77 | MAOA (0.39) | KDM4ETDP1ALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | claimed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | claimed |
| US-11964042-B2 | Additive for medicinal agents | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-04-23 | — | — | US | disclosed |
| US-20220401761-A1 | Skin External Preparation for Cellulite Improvement and Cellulite Improvement Method | TOYO SUGAR REFINING CO., LTD. (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-4053142-A1 | EXTERNAL SKIN PREPARATION FOR AMELIORATING CELLULITE AND METHOD FOR AMELIORATING CELLULITE | Toyo Sugar Refining Co., Ltd. (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202688-A1 | ADDITIVE FOR MEDICINAL AGENTS | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| CN-113329663-A | Cosmetic unit | 松下知识产权经营株式会社 | 2021-08-31 | — | — | CN | disclosed |
| US-10022363-B2 | Pharmaceutical topical compositions | FERRER INTERNACIONAL, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-20160243104-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2016-08-25 | — | — | US | disclosed |
| US-9399014-B2 | Pharmaceutical topical compositions | FERRER INTERNACIONAL, S.A. (ES) | 2016-07-26 | — | — | US | disclosed |
| US-20160030338-A1 | Pharmaceutical Topical Compositions | FERRER INT (ES) | 2016-02-04 | — | — | US | disclosed |
| WO-2010043717-A2 | PHARMACEUTICAL TOPICAL COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177208-A1 | Pharmaceutical topical compositions | FERRER INTERNACIONAL, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2120846-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1613302-A2 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087740-A2 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040198639-A1 | Preserved and stable compositions containing peptide copper complexes and methods related thereto | PROCYTE CORPORATION | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202688-A1 | ADDITIVE FOR MEDICINAL AGENTS | ADM2, NQO1, MRPL21 | MRGPRX4 3528/4885RXRA 3393/4885RXRB 3764/4885 |
| US-10022363-B2 | Pharmaceutical topical compositions | CYP51A1, CUTA, LSS | MRGPRX4 2754/4885RXRA 1700/4885RXRB 1716/4885 |
| US-20160243104-A1 | PHARMACEUTICAL TOPICAL COMPOSITIONS | CYP51A1, CUTA, LSS | MRGPRX4 2754/4885RXRA 1700/4885RXRB 1716/4885 |
| US-20040198639-A1 | Preserved and stable compositions containing peptide copper complexes and methods related thereto | AOC1, NONO, CUTA | MRGPRX4 2394/4885RXRA 3395/4885RXRB 3606/4885 |
| US-11964042-B2 | Additive for medicinal agents | ADM2, NQO1, MRPL21 | MRGPRX4 3528/4885RXRA 3393/4885RXRB 3764/4885 |
| US-20220401761-A1 | Skin External Preparation for Cellulite Improvement and Cellulite Improvement Method | CUTA, GANC, ENGASE | MRGPRX4 3329/4885RXRA 3737/4885RXRB 4231/4885 |
| US-20160030338-A1 | Pharmaceutical Topical Compositions | CYP51A1, CUTA, LSS | MRGPRX4 2754/4885RXRA 1700/4885RXRB 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.